180 related articles for article (PubMed ID: 12820311)
1. Atypical courses of serum tumor markers--4 case reports.
Klapdor R; Bahlo M; Babinski A
Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
5. Investigation of serum tumor markers in the diagnosis of gastric cancer.
Fan B; Xiong B
Hepatogastroenterology; 2011; 58(105):239-45. PubMed ID: 21510322
[TBL] [Abstract][Full Text] [Related]
6. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
[TBL] [Abstract][Full Text] [Related]
8. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients.
Spila A; Roselli M; Cosimelli M; Ferroni P; Cavaliere F; Arcuri R; Tedesco M; Carlini S; D'Alessandro R; Perri P; Casciani CU; Greiner JW; Schlom J; Guadagni F
Anticancer Res; 1996; 16(4B):2241-7. PubMed ID: 8694550
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
12. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
13. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
Caponetti R; Caponetti T; Vici P
Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
15. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma.
Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Casaldi V; Cavaliere F; Carlini M; Garofalo A; Rinaldi G
Anticancer Res; 1993; 13(6B):2409-13. PubMed ID: 8135475
[TBL] [Abstract][Full Text] [Related]
16. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
19. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
